Related references
Note: Only part of the references are listed.Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers
Barbara Sperner-Unterweger et al.
IMMUNOBIOLOGY (2011)
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
Xin An et al.
BIOMARKERS (2010)
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
Shiqian Zhang et al.
BMC CANCER (2010)
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
N. Leffers et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Juan R. Cubillos-Ruiz et al.
CELL CYCLE (2010)
A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102
Lavakumar Karyampudi et al.
CLINICAL CANCER RESEARCH (2010)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
Jason A. Konner et al.
CLINICAL CANCER RESEARCH (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison
H. S. Kim et al.
EJSO (2010)
Pertuzumab for the treatment of ovarian cancer
Simon P. Langdon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Farletuzumab in epithelial ovarian carcinoma
Whitney A. Spannuth et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer
Hideaki Shimada et al.
GASTRIC CANCER (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
Pei-Rong Ding et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2010)
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Deborah L. White et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel
P. Hoskins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2010)
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Jennifer A. Belisle et al.
MOLECULAR CANCER (2010)
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells
S. Bafna et al.
ONCOGENE (2010)
MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells
M. P. Ponnusamy et al.
ONCOGENE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Jason A. Wilken et al.
JOURNAL OF OVARIAN RESEARCH (2010)
Innate IL-17-producing cells: the sentinels of the immune system
Daniel J. Cua et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Ilona Kryczek et al.
BLOOD (2009)
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Ryan A. Wilcox et al.
BLOOD (2009)
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
Jessica N. McAlpine et al.
BMC CANCER (2009)
Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells
Fang-qiu Li et al.
BMC CANCER (2009)
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
Kui Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
HanByoul Cho et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
Ninke Leffers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
Uciane K. Scarlett et al.
CANCER RESEARCH (2009)
The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Markus Munz et al.
CANCER RESEARCH (2009)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
Mark J. Dobrzanski et al.
CLINICAL IMMUNOLOGY (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
Ninke Leffers et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Ovarian Cancer Cells Induce Peripheral Mature Dendritic Cells to Differentiate Into Macrophagelike Cells In Vitro
Fangxue Chen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Pravin T. P. Kaumaya et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Kiavash Movahedi et al.
BLOOD (2008)
MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
M. P. Ponnusamy et al.
BRITISH JOURNAL OF CANCER (2008)
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer
Kimberly R. Kalli et al.
CANCER RESEARCH (2008)
MUC4, a Multifunctional Transmembrane Glycoprotein, Induces Oncogenic Transformation of NIH3T3 Mouse Fibroblast Cells
Sangeeta Bafna et al.
CANCER RESEARCH (2008)
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity
Eduardo Huarte et al.
CANCER RESEARCH (2008)
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer
Michael J. Callahan et al.
CLINICAL CANCER RESEARCH (2008)
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
Catherine S. M. Diefenbach et al.
CLINICAL CANCER RESEARCH (2008)
Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer
I. Wertel et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2008)
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kimberly R. Kalli et al.
GYNECOLOGIC ONCOLOGY (2008)
Rationale for folate receptor alpha targeted therapy in high risk endometrial carcinomas
Monica Brown Jones et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
Angele L. M. Oei et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Reversal of drug resistance in ovarian cancer: Where do we go from here?
Stan B. Kaye
JOURNAL OF CLINICAL ONCOLOGY (2008)
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D
Mathias Krockenberger et al.
JOURNAL OF IMMUNOLOGY (2008)
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
Je-In Youn et al.
JOURNAL OF IMMUNOLOGY (2008)
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
Kimberly A. Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
Peter M. Smith-Jones et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Ovarian cancer cells modulate human blood neutrophils response to activation in vitro
M. Klink et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2008)
NKG2D ligands:: key targets of the immune response
Segundo Gonzalez et al.
TRENDS IN IMMUNOLOGY (2008)
The NKG2D receptor: sensing stressed cells
Carlos Lopez-Larrea et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Koebel et al.
PLOS MEDICINE (2008)
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
Steffen Runz et al.
GYNECOLOGIC ONCOLOGY (2007)
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers
Gilberto Filaci et al.
JOURNAL OF IMMUNOLOGY (2007)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy
Annechien Lambeck et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Characterisation of the new EpCAM-specific antibody HO-3:: implications for trifunctional antibody immunotherapy of cancer
P. Ruf et al.
BRITISH JOURNAL OF CANCER (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
PD-1 and its ligands in T-cell immunity
Mary E. Keir et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
Louis A. Dainty et al.
GYNECOLOGIC ONCOLOGY (2007)
Rapid evolution of cancer/testis genes on the X chromosome
Brian J. Stevenson et al.
BMC GENOMICS (2007)
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes
Eliana Bignotti et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer
Kathryn L. Terry et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance
Li Wang et al.
GYNECOLOGIC ONCOLOGY (2007)
CD4 regulatory T cells in human cancer pathogenesis
Keith L. Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)
Subhash C. Chauhan et al.
MODERN PATHOLOGY (2006)
ErbB-3 predicts survival in ovarian cancer
Berno Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer
Keith L. Knutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types
Huamin Wang et al.
MODERN PATHOLOGY (2006)
Dendritic cells and tumor microenvironment: A dangerous liaison
Ingo Fricke et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
The role of folate receptor α in cancer development, progression and treatment:: Cause, consequence or innocent bystander?
Linda E. Kelemen
INTERNATIONAL JOURNAL OF CANCER (2006)
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells
Rongcun Yang et al.
CANCER RESEARCH (2006)
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels
J. M. Lancaster et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas
AP Singh et al.
PROSTATE (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
HP Dong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
V Goodell et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
P Serafini et al.
SEMINARS IN CANCER BIOLOGY (2006)
Expression of synovial sarcoma x (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 Epitopes recognized by CD4+ T cells
D Valmori et al.
CLINICAL CANCER RESEARCH (2006)
Foxp3 expressing CD4(+) CD25(+) and CD8(+)CD28(-) T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma
Federica Meloni et al.
HUMAN IMMUNOLOGY (2006)
Adoptive T cell therapy of solid cancers
KL Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Role of folate receptor genes in reproduction and related cancers
H Elnakat et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
MS Patankar et al.
GYNECOLOGIC ONCOLOGY (2005)
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma
S Wei et al.
CANCER RESEARCH (2005)
A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers
SK Halder et al.
NEOPLASIA (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Mechanisms of suppression by suppressor T cells
H von Boehmer
NATURE IMMUNOLOGY (2005)
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
N Parker et al.
ANALYTICAL BIOCHEMISTRY (2005)
Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell
B Perussia et al.
MOLECULAR IMMUNOLOGY (2005)
The granule pathway of programmed cell death
PG Ashton-Rickardt
CRITICAL REVIEWS IN IMMUNOLOGY (2005)
Expression of sperm protein 17 (Sp17) in ovarian cancer
JM Straughn et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer
S Baron-Hay et al.
CLINICAL CANCER RESEARCH (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma - From the Danish MALOVA ovarian cancer study
EVS Hogdall et al.
CANCER (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice
AM Ercolini et al.
JOURNAL OF IMMUNOLOGY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool
M Hofmann et al.
CANCER CYTOPATHOLOGY (2002)
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
WP Zou et al.
NATURE MEDICINE (2001)
Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
BWT Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
